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Objectives. To compare 1% and 3% POL foam in treating the great saphenous vein (GSV) by ultrasound guided
sclerotherapy.
Design. Multicentre, prospective, randomised, double-blind trial with 2 year-follow-up.
Patients and methods. 148 patients with GSV reflux (saphenous trunk diameter 4e8 mm) were randomised to undergo
ultrasound guided foam sclerotherapy using either 1% or 3% POL foam in a single session. Foam production was stand-
ardised using a sterile disposable syringe kit including sterile air and the Turbofoam machine. Duplex ultrasonography
was used to assess the outcome at 3 weeks, 6 months, 1 year, 18 months and 2 years. The main criterion of success was the
disappearance of the venous reflux. The length of occlusion of the vein (only measured at 3 week-echography assessment)
was a secondary criterion. Side effects were assessed.
Results. 74 patients were included in each group.
The mean volume of foam injected was 4.4 ml for the 3% group and 4.6 ml for the 1% group. After 3 weeks, reflux was
abolished in 96% (71 patients) of the 3% group and 88% (68 patients) of the 1% group (NS). The mean occlusion length of
the vein was 38 cm for the 3% group and 34 for the 1% group (NS). After 2-years, reflux was absent in 69% of the 3%
group and 68% of the 1% group (NS). 14 patients were lost to follow-up at 2 years.
Conclusion. This study demonstrates equivalent efficacy for 1% POL and 3% POL foam in sclerotherapy of the GSV
where the trunk is less than 8 mm in diameter. These data obtained two years of follow-up confirm our previously reported
6 month-follow-up data published in 2005.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Keywords: Varicose veins; Sclerotherapy; Foam sclerotherapy; Foam sclerosant; Ultrasound guided sclerotherapy;
Polidocanol.
Eur J Vasc Endovasc Surg 34, 723e729 (2007)
doi:10.1016/j.ejvs.2007.07.014, available online at http://www.sciencedirect.com onIntroduction
Limited clinical evidence supports the use of sclero-
therapy in clinical practice.1,2 Recent enhancements
of this technique including ultrasound-guided sclero-
therapy (UGS)3,4 and foam sclerosant agents5,6 have
contributed greatly to the efficacy of this method.7
As a result UGS is becoming established as a technique
in its own right for the treatment of incompetent sa-
phenous veins. A shortage of well-conducted clinical
trials and the absence of standardised procedures
for sclerotherapy and foam production continue to
*Corresponding author. Dr. C. Hamel-Desnos, MD, Centre Hospital-
ier Prive´ Saint Martin, 18 rue des Roquemonts, 14050 Caen, France.
E-mail address: claudine@desnos.eu1078–5884/000723+ 07 $32.00/0  2007 European Society for Vascuhinder the process of obtaining a higher-grade
recommendation.
In 2003 we published data demonstrating con-
siderable superiority of foam compared to liquid 3%
polidocanol (POL) in sclerotherapy of the great saphe-
nous vein (GSV). We observed 85% success rate for
a single injection of foam compared to 35% for liquid
in abolishing reflux in the GSV.7,8 These results
were confirmed by a Japanese study in 2004.9 We
used the same volume of foam and liquid, but the
quantity of active substance was 5 times less for the
foam compared to the liquid. Efficacy in obliterating
the vein with foam was twice that for the liquid
sclerosant.
Compared to liquid sclerosants, the doses of
foamed sclerosants should be reduced in volume10lar Surgery. Published by Elsevier Ltd. All rights reserved.
724 C. Hamel-Desnos et al.and in concentration. Histological studies performed
on human endothelial cells placed in contact with var-
ious concentrations of sclerosing liquid and foam con-
cord with this.11 Endothelial destruction was identical
in appearance for concentrations of 0.5% POL foam
and 3% POL liquid (1.5 seconds’ contact).
The aim of this study is to compare the efficacy of
foams made from 1% and 3% POL since this has not
been studied systematically. To ensure comparability
between sclerotherapists, foam was prepared using
the Turbofoam machine, which was available in
each of the 5 investigative centres. A detailed protocol
for this randomised trial as well as early results after
6 months of follow-up were published in 2005.12
Methods
This multicentre, prospective, randomised, double-
blind trial was sponsored by the Socie´te´ Franc¸aise
de Phle´bologie and carried out in 5 centres. One addi-
tional independent centre was responsible for overall
data collection and statistics. The study was approved
by the Normandy Ethics Committee (registered on
15.05.2003 under No. 2003/015). It complies with the
Declaration of Helsinki (1964) according to its latest
version (Hong Kong 1989). Patients who gave in-
formed written consent were considered for inclusion
in the study.
Pre-calculation of required sample size was under-
taken using a Casagrande/Pike calculation formula
on the basis of a unilateral superiority trial where
3% would have a success rate of 85% and that 1%
would be inferior by at least 20%. This resulted in
a minimum sample of 140 patients with alpha¼ 0.05
and Beta¼ 0.10. In each centre, a randomization list
was created by the statistician and a series of num-
bered ampoules of Aethoxysklerol (concentration
not indicated) was provided by Kreussler Laborato-
ries (Photo 1). Each treatment was assigned to the pa-
tients according to the randomisation list. Statistical
analysis was conducted on blinded data and the un-
blinding was done after writing of the statistical
report.
Patients considered for inclusion in this study were
of either sex presenting with varices arising from
incompetence of the GSV, with or without sapheno-
femoral junction (SFJ) incompetence. The size of the
GSV was limited to those with a diameter of between
4 and 8 mm, measured below the SFJ while the patient
was standing. All CEAP classes between C2 and C6
(Ep, As2, Pr) were allowed. Patients presenting a con-
traindication to sclerotherapy in general and/or to
Eur J Vasc Endovasc Surg Vol 34, December 2007POL in particular were not included. Inclusion and
exclusion criteria are shown in Table 1.
The success of treatment was assessed by duplex
ultrasonography. Patients were evaluated in the
standing position according to the authors’ usual
practice. Flow was elicited by manual compression
of the calf, followed by release. Reflux was considered
to be present if reverse flow persisted for 1 or more
seconds.
The primary outcome criterion was abolition of
venous reflux at 2 years. Interim assessments were
undertaken at 3 weeks and absence of recurrence of
reflux was checked at 6 months, 1 year and 18 months.
The secondary outcome criterion was the length of
occluded vein assessed by duplex ultrasonography.
This was only measured at the 3 week assessment.
The local and systemic complication rates were also
recorded as part of the study, including visual distur-
bance and chest symptoms.
Patients who were found to have residual incompe-
tence of the GSV at the 3-week assessment were
allowed to withdraw from further study assessments
and resume management of their clinical varices.
These were considered to be treatment failures and
counted as a treatment failure when analysing the
study data.
Foam production
Foam production was obtained using a sterile dispos-
able syringe kit including sterile air and the TURBO-
FOAM system (Kreussler Pharma, Wiesbaden,
Germany) Photo 2. This machine includes a micropro-
cessor, which standardises the pressure, the speed and
the number of movements of the syringes used to pro-
duce sclerosant foam.13 One of the syringes was filled
with 2 ml Aethoxysklerol and 8 ml sterile air giving
Photograph 1. Numbered ampoules of Aethoxysklerol.
7251% vs 3% POL Foam in Sclerotherapy of the GSVTable 1. Inclusion and exclusion criteria e 3/1 Study
Inclusion criteria Exclusion criteria
Patient of either sex or any ethnic group.
Age between 18 and 80 years, inclusive.
Agreeing to take part in the study and having given written
informed consent.
Presenting with incompetence of the GSV: reflux of SFJ + trunk
or reflux of trunk of the GSV in the thigh, with or without
incompetence below the knee, with a diameter below the SFJ
of between 4 and 8 mm inclusive (patient standing). Reflux
measured on Doppler ultrasound must be greater than or
equal to 1 second.
CEAP classifications authorised: C2 to C6, Ep, AS2, Pr.
Patient presenting a state or history of mental or psychiatric
disorder or any factor limiting the ability to take part in the
study in an informed and compliant way.
Informed consent not signed.
Patient with incompetence of SFJ of the GSV without trunk
incompetence of the GSV at the thigh or trunk incompetence
below the knee without trunk incompetence of the GSV at the
thigh.
Patient with chronic liver disease.
Renal impairment (creatininemia> 150 micromol/l).
Women who are pregnant or breastfeeding.
Women with a risk of becoming pregnant during the course of
treatment (absence of effective contraception).
Material or geographical impossibility of taking part in the study.
Patient with a known progressive malignant disease.
Patient with uncontrolled hypertension.
Patient with cardiac or respiratory failure.
Patient with a personal history of deep vein thrombosis.
Patient with known acquired or constitutional coagulopathy.
Patient intolerant to alcohol or having taken, in the past month,
a product blocking the metabolisation of ethyl alcohol (e.g.
Esperal).
Patient with a known allergy to Lauromacrogol 400 or
Polidocanol.
GSV: Great Saphenous Vein.
SFJ: Sapheno-Femoral Junction.a sclerosant liquideair mixture of 1þ 4. The charac-
teristics of the foam obtained were assessed in an
independent laboratory* using diffuse transmission
spectroscopy and the range of bubble size was:
e Aethoxysklerol 1% and 3%: 70e100 mm 20 sec-
onds after preparing the foam.
e Aethoxysklerol 1% and 3%: 100e140 mm 40 sec-
onds after preparing the foam.
Treatment
One treatment session with sclerosant foam was car-
ried out, and no further injection of the GSV was al-
lowed during the follow-up period of 2 years. This
contrasts with our standard practice of obliterating
all varices by a course of sclerotherapy but allows ob-
jective assessment of the efficacy of the two strengths
of foam. Patients lay supine during treatment. All in-
jections were given under ultrasound guidance and
performed using the direct puncture technique.7,12,13
The first injection (2.5 ml foam) was given at the junc-
tion between the upper and middle-third of the thigh.
If necessary, up to 2 more injections were allowed into
the GSV in the thigh (total foam volume not exceeding
*Universite´ de Marne la Valle´e-France. Laboratoire de physique des
milieux divise´s et interfaces. CNRS.7.5 ml). The development of venospasm in the treated
vein and the observation that the vein was completely
filled by foam on the ultrasound image was used to
judge satisfactory completion of the treatment session.
No concomitant treatment was carried out to other
varices or saphenous trunks. No special precaution
was taken after the injections to prevent foam entering
the deep veins or to protect the limb from deep vein
thrombosis. No leg elevation, no compression of the
SFJ and no ankle dorsiflexion was used. Patients re-
ceived no special post-operative instructions regarding
Photograph 2. TurboFoam device.
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726 C. Hamel-Desnos et al.exercise or walking. Compression bandages or stock-
ings were not applied to the limb following treatment,
in keeping with our usual practice for saphenous
trunks. Elastic compression, analgesic or anti-inflam-
matory drugs were only prescribed if secondary in-
flammation or painful reactions occurred.
After the initial treatment session, all investigators
were invited to provide their own impression of the
concentration of the sclerosant which they had in-
jected by completing an item on the report form for
each patient. This was an assessment of whether there
were any clearly obvious differences of the immediate
effects of treatment with 1% or 3% POL foam.
Follow up
Patients were reviewed after 3 weeks for clinical and
duplex ultrasound examination. Further clinical and
duplex ultrasound examinations were performed
every 6 months thereafter for 2 years, unless the
patient was withdrawn from further follow-up assess-
ments if the treatment failed to close the GSV. These
patients remained in the study as far as the assess-
ment of treatment efficacy was concerned with the
outcome recorded in the results as a failure. Addi-
tional or alternative treatment was offered to patients
in whom the single treatment session failed to obliter-
ate the GSV. At each assessment the presence of
venous reflux in the GSV was sought on ultrasonogra-
phy. We recorded disappearance of the successfully
treated GSV when it could no longer be visualised
in the thigh by B mode imaging. The diameter of
incompetent veins was measured.
Statistics
Data were described by the number of veins or limbs
and percentage and quantitative data by mean and
standard deviation. Contingency tables were analysed
using a Chi squared test and comparison of means an-
ova. The level of statistical significance was taken as
0.05. Data were analysed using SAS software V. 8.2.
Results
Between September 2003 to January 2004, 148 patients
were included in the study and were randomly allo-
cated to the treatment groups. Patient characteristics
were similar in the two groups (Table 2). 38% of pa-
tients presented with isolated truncal reflux and 62%
presented with truncalþ SFJ reflux and these were
evenly distributed in the two study groups. Most pa-
tients were treated by one or two injections with only
Eur J Vasc Endovasc Surg Vol 34, December 200716% of patients requiring a third injection. Venous
spasm was obtained in 99% of cases. One patient expe-
rienced flushing and a sensation of tightening in the
throat, which resolved spontaneously within a few
minutes. No other adverse event was observed.
The investigators’ assessment of the strength of
sclerosant foam was evaluated after 2 years when un-
blinding was done. In 71% of cases, the investigators
failed to identify the solution which had been used.
In 50% of cases the answer was ‘‘no idea’’ and in
21% of cases the answer was wrong. The authors are
confident that the sclerotherapists were effectively
blinded to the treatment that they had given.
All 148 patients were seen again at the 3-week re-
view. Five patients came for an intermediate visit (be-
fore follow-up at 3 weeks) for the following reasons:
e pain in the lower limb: 2 cases
e ecchymosis: 1
e inflammation and pain in the thigh: 1 (DVT on
D19, discussed below)
e inflammation in the leg with lump (thrombectomy
was performed): 1
At 3weeks, a fewminor secondary effectswere pres-
ent (Table 3). Minor ecchymoses persisted in 2 cases. In
3 cases, skin inflammation was more painful, with
lumps (thrombophlebitis): for 2 of them a thrombec-
tomy was performed (one at an intermediate visit, cf).
There were also 3 undesirable events which were
probably not linked to treatment (1 lower back pain,
1 localised pain 24 h after the session, 1 asthenia for
8 days after the session), but another more serious
event e segmental thrombosis of the common femoral
vein (CFV) e occurred in the 3% group. This thrombo-
sis was a parietal, non-obstructive clot that extended
from the ipsilateral GSV as an extension of thrombus
from the GSV into the SFJ. Thrombus dimension in
the CFV was 4 mm maximum thickness with a length
of about 2 cm. It was fixed to the anterior wall of the
Table 2. General inclusion data e 3/1 Study
3% Group (N¼ 74) 1% Group (N¼ 74)
Sex Women 80% (n¼ 59) Women 78% (58)
Chi: 0.04 p: N.S. Men 20% (n¼ 15) Men 22% (16)
Mean age 53 years S.D. 15 56 years S.D. 14
Anova: 1.82 p: N.S.
Mean saphenous
vein diameter
6.1 mm S.D. 1.3 6.1 mm S.D. 1.3
Anova: 0.06 p: N.S.
Isolated truncal reflux 39% 36%
Truncalþ SFJ reflux 61% 64%
Chi: 0.73 p: N.S.
Mean injected volumes 4.4 ml S.D. 1.8 4.6 ml S.D. 1.6
Anova: 0.52 p: N.S.
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s.CFV. The GSV was obliterated throughout its entire
length (75 cm). The episode was diagnosed on day
19, after the patient had sought advice for pain in
the thigh. This patient had received a total of 7.5 ml
of foam for a GSV measuring 7 mm in diameter. At
the time of inclusion, he had reported 2 previous ep-
isodes of spontaneous superficial venous thrombosis
(SVT). He was managed by elastic compression, full
anticoagulation with low molecular weight heparin
and oral anticoagulants for 3 months. Other authors
suggest treating non-occlusive thrombosis by elastic
compression only.14 The thrombus disappeared com-
pletely after 3 weeks and the GSV remained obliter-
ated at 2 years. Thrombophilia screening showed
a high factor VIII level (225%) combined with
hyperhomocysteinaemia.
Diagram 1 summarises the findings during the 2-
year follow-up period. The outcome of treatment
was the same at each treatment point as far as disap-
pearance of reflux was concerned. At 2 years, the suc-
cess rates were 68% for 1% Aethoxysklerol, and 69%
for 3% Aethoxysklerol (NS). (14 lost to follow-up: 9
for the 1% group and 5 for the 3% group).
In recanalised GSVs with recurrence of reflux, the
mean diameter of the new channel was 2.8 mm e
compared to the initial mean diameter of 6.1 mm,
i.e. the diameter was reduced by more than half.
This problem was readily resolved by a further sclero-
therapy session.
For the 1% group, in the case of isolated truncal
reflux, the success rate at 3 weeks was 76%, whereas
it was 63% in the case of truncalþ SFJ reflux (NS
Chi-square 0.27).
For the 3% group, the respective success rates were
78% and 64% (NS Chi-square 0.22).
0
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Diagram 1. Elimination of reflux (E.R) in the great saphe-
nous vein and disappearance of the GSV or image of an
echogenic string (at the thigh level) in B mode e 3/1 Study.
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728 C. Hamel-Desnos et al.At the 2 year-follow-up interval, the situation was
unchanged within each group (NS). The rate of recan-
alisation was not significantly lower for the 3% group
than for the 1% group in GSVs with an incompetent
SFJ (37% recanalisation for the 1% group and 36%
for the 3% group; Chi-square 0.96).
Discussion
The outcome of ultrasound guided foam sclerother-
apy has been reported in several clinical series but
few randomised trials. Clinical series report good re-
sults for sclerotherapy of saphenous trunks.5e9,14e22
Some authors, including Barrett,19 have also reported
excellent levels of satisfaction and improvement in
patients’ quality of life. Some series have included de-
tailed analysis of the incidence of side effects to treat-
ment.19,23 Our present study is a ‘‘dose-finding’’
study, seeking only to answer the question whether
1% or 3% POL foam is the more effective.
We treated only the GSV in the thigh, ignoring vari-
ces, perforators and other saphenous veins.
The main outcome variable, abolition of venous
reflux assessed by duplex ultrasonography, reflects
a pure indicator of success or failure. This cannot be
judged reliably on clinical criteria since a clinical
recurrence of varicose veins may not be obvious for
several years following sclerotherapy.24
Each practitioner assessed the results of his own
treatment, but since he was unaware of the strength
of foam injected into each patient, his conclusions
about the outcome were unbiased.
In the course of the study we showed that it was
not possible to identify the strength of the injected
foam from the response of the saphenous trunk and
therefore the investigators were blinded to the treat-
ment that they were giving. Clinical criteria were
taken into account by each practitioner at each consul-
tation but were not used to evaluate outcome.
We standardised themethodofpreparing foamas far
as was possible, since Tessari’s three-way tap-method25
yields foam with variable physical characteristics26
even though this is a very widely used technique.
Each centre used the Turbofoam system ensuring that
the sclerosant was the same in each of the 5 centres.
In a comparative study of 80 cases of GSV treat-
ments, Ceulen showed no statistical difference in effi-
cacy (occlusion) for 1% and 3% POL foams at 1 year
follow-up.27 Despite this he is convinced that 3%
should be a more efficient concentration with a larger
study required to demonstrate this. Our own results
at 2 years, with almost double number of patients,
confirm equivalent efficacy for the two treatments.
Eur J Vasc Endovasc Surg Vol 34, December 2007In a large series with 3 years follow-up, Myers reports
better efficacy for 1.5% and 1% concentrations com-
pared to lower concentrations or to 3% sclerosant.28
We acknowledge that long-term outcomes (e.g. 5
years) may be different but no clinical trial of foam
sclerotherapy has been published with such a long
period of follow-up.
The average injected volume was similar in the two
groups, although we had expected that a higher vol-
ume would have been required in the 1% group.
The actual mean volume of sclerosant required was
small (4.4e4.6 ml) compared to that used by some au-
thors. In the foam versus liquid study, volumes (liquid
or foam) were 2 or 2.5 ml using 3% Aethoxysklerol
only, with good outcomes for foam.7,8 These data con-
firm the recommendations from the Tegernsee Con-
sensus10 and other authors’ experiences15,27,29: large
volumes seem not to be necessary in order to close
medium calibre saphenous trunks. Our study shows
that the risk of recanalisation is unrelated to the con-
centration of sclerosant or to the coexistence of SFJ in-
competence. There may be a relationship to the total
injected volume but other so far unidentified factors
are probably also important.
We found that the disappearance of the GSV on
ultrasonography begins after 6months following treat-
ment in 30% of cases. However in many patients this
occurs more slowly so an image of an echogenic string
or disappearance of the vein sometimes occurs as late
as 18 months or 2 years (63% at 1 year, 80% at 18
months, 85% at 2 years). In our trial, the concentration
of the injected foam had no influence on the onset of
disappearance, nor on the speed of its occurrence (no
difference between the 2 groups e Chi squared: N.S.).
In our study, the modest volume of sclerosant re-
sulted in few adverse events. The only serious problem
was a non-occlusive thrombus extending into the CFV
in a patient with a previously undiagnosed thrombo-
philia. The only clue to this in his medical history was
some episodes of SVT. Since thrombophilias are com-
mon and deep vein thrombosis is uncommon following
sclerotherapy, it is probably inappropriate to check
each patient for thrombophilia prior to sclerotherapy.
Our direct puncture technique gives flexibility and
adaptability in treating saphenous veins.
We used the development of vasospasm and filling
of the vein on ultrasound imaging to judge whether
a sufficient foam volume had been injected. This en-
abled us to minimise the volume of foam required,
thus obtaining a low complication rate. This is proba-
bly the reason why we can avoid routine compression
treatment after sclerotherapy of trunks. In the present
study therefore, delayed elastic compression was
applied only 3 times.
7291% vs 3% POL Foam in Sclerotherapy of the GSVConclusion
In a previous randomised trial, we have demonstrated
the clear superiority of 3% POL foam compared to
POL as a liquid sclerosant in treatment of GSV. We
have now investigated the use of 1% and 3% POL
foam in sclerotherapy of the GSV. No difference was
found between these two foams in the immediate re-
sponse to injection or in the rate of recanalisation after
two years. These outcomes are in line with other stud-
ies evaluating the efficacy of different concentrations
but no long-term trials have so far been reported.
Recanalisation was observed in about one third of
saphenous veins managed in this way. However, this
was a clinical research study and is not comparable
withoureverydaypractice.We consider that the efficacy
of treatment was prejudiced by not treating saphenous
tributaries, perforators or other varices. In addition, we
did not permit subsequent treatment sessions in which
any untreated veinwas addressed. This strategywas es-
sential in order to compare the efficacy of different
strengths of sclerosant foam under identical conditions.
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